NEOSTIGMINE METHYLSULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Neostigmine Methylsulfate patents expire, and what generic alternatives are available?
Neostigmine Methylsulfate is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Amring Pharms, Be Pharms, Caplin, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Indoco, Meitheal, Nivagen Pharms Inc, Par Sterile Products, and Sagent Pharms Inc. and is included in eighteen NDAs.
The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are nine drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Neostigmine Methylsulfate
A generic version of NEOSTIGMINE METHYLSULFATE was approved as neostigmine methylsulfate by FRESENIUS KABI USA on January 8th, 2015.
Summary for NEOSTIGMINE METHYLSULFATE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 18 |
Finished Product Suppliers / Packagers: | 24 |
Raw Ingredient (Bulk) Api Vendors: | 104 |
Clinical Trials: | 9 |
Patent Applications: | 1,171 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for NEOSTIGMINE METHYLSULFATE |
What excipients (inactive ingredients) are in NEOSTIGMINE METHYLSULFATE? | NEOSTIGMINE METHYLSULFATE excipients list |
DailyMed Link: | NEOSTIGMINE METHYLSULFATE at DailyMed |
Recent Clinical Trials for NEOSTIGMINE METHYLSULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Seoul National University Hospital | N/A |
Alexandria University | Phase 4 |
Kasr El Aini Hospital | Phase 4 |
Pharmacology for NEOSTIGMINE METHYLSULFATE
Drug Class | Cholinesterase Inhibitor |
Mechanism of Action | Cholinesterase Inhibitors |